Study Title | D0816C00025: A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours |
---|---|
Protocol ID | D0816C00025 |
Disease (Sub Disease) | Solid Tumours |
Diagnosis Stage | Relapsed/refractory |
Location | NSW / WA |
Sponsor | AstraZeneca |
Links | https://clinicaltrials.gov/ct2/show/NCT04236414 |
Trial Status | Open |
Trial Open Date | 01/11/2022 |
Sites | Perth Children's Hospital / Sydney Children's Hospital |
Study Type | Treatment |
Phase | Phase 1 |
Age Eligibility | 0 Years to 18 Years |
International registry ID's | NCT04236414 |